5 Reasons Robotic Surgery Is Reshaping Head and Neck Oncology in China
In the tightly controlled corridors of China’s leading academic hospitals, a quiet revolution is unfolding—one that hinges not on new drugs or gene therapies, but on the precise, steady hand of a machine. Transoral robotic surgery, or TORS, once a niche experimental technique pioneered in the United States, has taken root in China’s head and neck oncology landscape with remarkable speed and strategic intent. Fueled by national priorities in medical innovation, growing clinical expertise, and a patient population increasingly wary of disfiguring open surgeries, TORS is no longer just an imported novelty—it is becoming a domestic standard of care for select tumors of the oropharynx, larynx, thyroid, and beyond.
The adoption of TORS in China reflects a broader trend: the country’s rapid integration of advanced surgical robotics into complex oncologic procedures. Unlike in Western countries where TORS initially gained traction through private hospital networks and industry partnerships, China’s rollout has been more centralized, often tied to academic medical centers affiliated with traditional Chinese medicine universities—ironically, institutions historically associated with herbal remedies and acupuncture, not high-tech robotics. Yet this convergence underscores a deliberate national strategy: to modernize healthcare delivery while anchoring it within existing institutional frameworks.
At the heart of this transformation lies the da Vinci Surgical System, the only robotic platform currently approved for TORS in China. Developed by Intuitive Surgical and first cleared by the U.S. FDA for head and neck use in 2009, the system’s three-component architecture—surgeon console, bedside robotic arms, and 3D high-definition vision system—enables operations through the natural orifice of the mouth, eliminating the need for external incisions. For patients with early-stage oropharyngeal cancer, this means avoiding the jaw-splitting approaches of the past, which often left them with chronic pain, malocclusion, and feeding tube dependence. For thyroid cancer patients, it offers a truly scarless alternative to the visible neck incision that has long been a source of psychological distress, particularly among younger women.
Clinical teams in Chengdu and Deyang have emerged as early adopters. Physicians such as Zhang Meng and Zhang Qinxiu at Chengdu University of Traditional Chinese Medicine and its affiliated hospitals have published some of the first Chinese-language reviews synthesizing global TORS evidence and adapting it to local practice patterns. Their work, while rooted in academic literature, speaks to a pragmatic reality: Chinese patients often present with concerns not just about survival, but about preserving voice, swallowing, and appearance—outcomes that TORS appears uniquely positioned to protect.
Take oropharyngeal cancer, for instance. Historically, treatment in China followed a bifurcated path: either radical open resection with functional compromise or radiotherapy with long-term toxicity. The rise of human papillomavirus (HPV)-negative oropharyngeal cancers in certain regions—distinct from the HPV-driven epidemic in the West—has complicated this picture. Yet TORS offers a middle ground. For T1–T2 tumors of the tonsil or base of tongue, surgeons can achieve complete resection with negative margins while preserving critical musculature. Postoperative swallowing function is markedly better than after open surgery, and tracheostomy or gastrostomy rates drop significantly. In a healthcare system under pressure to reduce hospital stays and postoperative complications, these functional advantages translate into tangible cost savings and improved patient satisfaction.
Equally compelling is TORS’s role in managing recurrent nasopharyngeal carcinoma—a disease with high incidence in Southern China and Southeast Asia. Despite excellent initial response rates to radiotherapy, up to 10–15% of patients experience local recurrence, often in anatomically treacherous zones near the skull base. Re-irradiation carries prohibitive toxicity, and open salvage surgery is fraught with morbidity. Here, TORS provides a minimally invasive corridor through the soft palate into the nasopharynx, allowing precise tumor debulking with minimal collateral damage. Early Chinese case series mirror international findings: two-year overall survival rates exceeding 80% in carefully selected patients, with acceptable complication profiles.
Laryngeal preservation is another frontier. While transoral laser microsurgery (TLM) remains the gold standard for early glottic and supraglottic cancers, its steep learning curve and limited instrument articulation have hindered widespread adoption outside elite centers. TORS, by contrast, offers intuitive wristed instrumentation and stereoscopic vision, enabling more consistent exposure of the anterior commissure or epiglottic vallecula. Preliminary data from Chinese cohorts suggest comparable oncologic outcomes to TLM—local control rates above 90% for T1–T2 disease—but with shorter learning curves and potentially better voice outcomes due to more precise tissue handling.
Even in benign conditions, TORS is finding footholds. Submandibular gland tumors, traditionally removed via a 5-cm incision beneath the jawline, can now be excised transorally, leaving no external scar. Though the procedure demands meticulous dissection around the lingual nerve and Wharton’s duct, early adopters report high patient satisfaction and low rates of permanent nerve injury. Similarly, robotic thyroidectomy via the vestibular approach—accessing the gland through tiny incisions inside the lower lip—has gained traction among endocrine surgeons seeking to meet aesthetic demands without compromising oncologic rigor.
Yet the path forward is not without obstacles. The most significant limitation remains reconstructive. While TORS excels at resection, it struggles with complex defect closure. Free flap reconstruction—the cornerstone of post-ablative rehabilitation in head and neck oncology—requires microvascular anastomosis in confined spaces, a task that even the da Vinci system handles imperfectly. Only a handful of centers globally, and none yet in China, have demonstrated reliable robotic-assisted free flap transfer. Until this barrier is overcome, TORS will remain restricted to smaller tumors with minimal tissue loss.
Cost is another constraint. The da Vinci system carries a price tag exceeding $2 million, with annual maintenance fees and per-procedure instrument costs that strain hospital budgets. In China’s tiered healthcare system, where reimbursement for robotic procedures is still evolving, access remains largely confined to Class A tertiary hospitals in major cities. Rural patients, who bear a disproportionate burden of late-stage head and neck cancers, rarely benefit.
Regulatory and training challenges compound the issue. Unlike in the U.S., where formal TORS fellowships and simulation curricula exist, Chinese surgeons often learn through observational visits or short-term proctorships. Standardized credentialing pathways are lacking, raising concerns about variability in outcomes. Moreover, while the National Medical Products Administration has approved the da Vinci system for certain indications, specific guidelines for TORS in head and neck oncology are still under development.
Despite these hurdles, the momentum is undeniable. The Chinese government’s “Healthy China 2030” initiative explicitly prioritizes surgical innovation and minimally invasive techniques. Provincial health commissions, such as Sichuan’s, have begun funding applied research projects on robotic surgery—evidence of institutional buy-in. Meanwhile, domestic companies are racing to develop homegrown surgical robots, though none have yet matched the da Vinci’s precision for transoral work.
Looking ahead, three developments could accelerate TORS adoption in China. First, the integration of artificial intelligence for intraoperative decision support—such as real-time margin assessment or nerve identification—could enhance safety and reduce reliance on surgeon experience. Second, the advent of single-port robotic platforms, which require only one oral incision instead of three, may further minimize trauma and simplify logistics. Third, and perhaps most importantly, the generation of high-quality, China-specific outcome data will be critical to convincing payers and policymakers of TORS’s value.
Already, multi-center registries are being planned to track functional and oncologic outcomes across diverse patient populations. If these efforts yield robust evidence—particularly on cost-effectiveness and quality of life—they could pave the way for broader insurance coverage and standardized clinical pathways.
In a field long defined by radical resections and life-altering complications, TORS represents more than a technical upgrade; it embodies a philosophical shift toward organ and function preservation. For Chinese patients, many of whom delay care due to fear of disfigurement or social stigma, this shift could be transformative. And for China’s medical system, it offers a chance to lead—not just in volume, but in the quality and humanity of cancer care.
As surgical robotics evolve from luxury to necessity, the question is no longer whether China will adopt TORS, but how quickly it can scale it equitably, safely, and sustainably. The answer will shape not only the future of head and neck oncology in Asia but also the global trajectory of minimally invasive cancer surgery.
Yuan Shunqi, Zhang Meng, Zhang Qinxiu
Department of Otorhinolaryngology–Head and Neck Surgery, School of Medicine and Life Sciences & Reproductive Health and Women’s and Children’s Hospital, Chengdu University of Traditional Chinese Medicine, Chengdu 610041, Sichuan, China; Department of Otorhinolaryngology–Head and Neck Surgery, People’s Hospital of Deyang City, Deyang Hospital Affiliated to Chengdu University of Traditional Chinese Medicine, Deyang 618000, Sichuan, China
Journal of Cancer Control and Treatment, 2022, 34(9): 868–873
DOI: 10.3969/j.issn.1674-0904.2021.09.014